Literature DB >> 27425197

Systemic inflammatory response syndrome (SIRS) after extracorporeal membrane oxygenation (ECMO): Incidence, risks and survivals.

Karthik Thangappan1, Nicholas C Cavarocchi1, Michael Baram2, Brandi Thoma3, Hitoshi Hirose4.   

Abstract

INTRODUCTION: Systemic inflammatory response syndrome (SIRS) is frequently observed after extracorporeal membrane oxygenation (ECMO) decannulation; however, these issues have not been investigated well in the past.
METHODS: Retrospective chart review was performed to identify post-ECMO SIRS phenomenon, defined by exhibiting 2/3 of the following criteria: fever, leukocytosis, and escalation of vasopressors. The patients were divided into 2 groups: patients with documented infections (Group I) and patients with true SIRS (Group TS) without any evidence of infection. Survival and pre-, intra- and post-ECMO risk factors were analyzed.
RESULTS: Among 62 ECMO survivors, 37 (60%) patients developed the post-ECMO SIRS phenomenon, including Group I (n = 22) and Group TS (n = 15). The 30-day survival rate of Group I and TS was 77% and 100%, respectively (p = 0.047), although risk factors were identical.
CONCLUSIONS: SIRS phenomenon after ECMO decannulation commonly occurs. Differentiating between the similar clinical presentations of SIRS and infection is important and will impact clinical outcomes.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ECMO; Infection; Outcomes; SIRS; Survival

Mesh:

Year:  2016        PMID: 27425197     DOI: 10.1016/j.hrtlng.2016.06.004

Source DB:  PubMed          Journal:  Heart Lung        ISSN: 0147-9563            Impact factor:   2.210


  2 in total

1.  EP-7041, a Factor XIa Inhibitor as a Potential Antithrombotic Strategy in Extracorporeal Membrane Oxygenation: A Brief Report.

Authors:  Charles V Pollack; Michael A Kurz; Neil J Hayward
Journal:  Crit Care Explor       Date:  2020-09-15

Review 2.  Inflammation and Oxidative Stress in the Context of Extracorporeal Cardiac and Pulmonary Support.

Authors:  Sanaz Hatami; Joshua Hefler; Darren H Freed
Journal:  Front Immunol       Date:  2022-03-04       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.